COPYRIGHT © DIGITAL JOURNAL INC. Sitemaps: XML / News. Digital Journal is not responsible for the content of external sites. Read more about our external linking
United States, Nevada, Las Vegas, DelveInsight’s “Oncolytic Virus Cancer Therapy – Market Insight, Epidemiology and Market Forecast – 2032” report provides current treatment practices, emerging drugs, Oncolytic Virus Cancer Therapy market share of the individual therapies, current and forecasted Oncolytic Virus Cancer Therapy market size from 2019 to 2032 segmented by seven major markets. The report also offers current Oncolytic Virus Cancer Therapy therapy algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Oncolytic Virus Cancer Therapy market.
Oncolytic Virus Cancer Therapy Overview
Oncolytic viruses (OVs), considered an effective anticancer strategy in recent years, are a special type of virus that are naturally or genetically engineered and can replicate preferentially in tumor cells and inhibit tumor growth. Oncolytic Virus Therapies is a treatment using a virus that can replicate itself to kill cancer cells. Many species of viruses exist, but not all can be designed to be oncolytic viruses (OV). The typical features of these OVs must include being non-pathogenic, the ability to target and kill the cancer cells, and the capacity to be transformed to express tumor-killing factors through genetic engineering methods.
Oncolytic Virus Cancer Therapy Epidemiological Insights
In 2021, the total Oncolytic Virus Therapies target patient pool cases across 7MM were about 6,32,000 which are expected to grow during the study period, i.e., 2019–2032.
Oncolytic Virus Cancer Therapy Treatment Market
Oocolytic Viruses have proven to be a powerful anticancer molecule, being able to be used for cancer diagnosis as well as treatment. Their multifunctional characteristics indicate good application prospects as cancer therapeutics, especially in combination with other therapies, such as radiotherapy, chemotherapy, and immunotherapy. Currently, only two oncolytic virus therapies are approved, namely, IMLYGIC (Talimogene laherparepvec/T-VEC; Amgen) approved in the US and Europe in 2015, and DELYTACT (teserpaturev/G47∆; Daiichi Sankyo) approved in Japan in 2021.
Discover more about Oncolytic Virus Cancer Therapy treatment therapies in the pipeline @ Oncolytic Virus Cancer Therapy Drugs
Leading Companies Working in the Oncolytic Virus Cancer Therapy Market
To understand key companies related to the Oncolytic Virus Cancer Therapy Market, get a snapshot of the Oncolytic Virus Cancer Therapy Regulatory and Patent Analysis.
Scope of the Oncolytic Virus Cancer Therapy Market Report
Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan]
Key Oncolytic Virus Cancer Therapy Companies: Targovax, Replimune, Genelux Corporation, Candel Therapeutics, DNAtrix, SillaJen, Treovir, Lokon Pharma AB, Istari Oncology, CG Oncology, Amgen, Daiichio Sankyo, and others
Therapeutic Assessment: Oncolytic Virus Cancer Therapy current marketed and emerging therapies
Oncolytic Virus Cancer Therapy Market Dynamics: Oncolytic Virus Cancer Therapy market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL’s views, Analyst’s views, Oncolytic Virus Cancer Therapy Market Access and Reimbursement
Table of Contents
Leading Reports by DelveInsight:
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Kritika Rehani
info@delveinsight.com
+1(919)321-6187